Hca Healthcare Inc Stock Price, News & Analysis

HCA Healthcare (NYSE: HCA) has announced its participation in the Bank of America 2025 Healthcare Conference. The presentation is scheduled for May 13, 2025, at 9:20 AM PT. Investors and interested parties can access the live audio webcast and presentation materials through HCA Healthcare's Investor Relations website at www.hcahealthcare.com. The company notes that dates and times may be subject to change and recommends checking the conference schedule or company website for the most current information.

HCA Healthcare (NYSE: HCA) reported strong Q1 2025 financial results with revenues reaching $18.321 billion, up from $17.339 billion in Q1 2024. Net income grew to $1.610 billion ($6.45 per diluted share) compared to $1.591 billion ($5.93 per diluted share) in Q1 2024.

Key operational metrics showed positive trends with same facility admissions increasing 2.6% and equivalent admissions up 2.8%. Emergency room visits rose 4.0%, while inpatient surgeries increased 0.2%. However, outpatient surgeries declined 2.1%. The company's Adjusted EBITDA reached $3.733 billion, up from $3.353 billion year-over-year.

During Q1 2025, HCA repurchased 7.762 million shares for $2.506 billion and declared a quarterly dividend of $0.72 per share. The company maintained its 2025 guidance, citing stable operating conditions and growing healthcare demand.

Two major clinical trials across 92 HCA Healthcare hospitals have demonstrated a breakthrough in improving antibiotic selection for hospitalized patients with abdominal or skin/soft tissue infections. The studies, involving over 316,000 patients, showed that computerized alerts helping clinicians choose appropriate antibiotics resulted in a 35% improvement in antibiotic selection for abdominal infections and a 28% improvement for skin/soft tissue infections.

The system uses patient-specific data from electronic medical records and hospital data to assess the risk of antibiotic-resistant infections. For low-risk patients, physicians were prompted to switch from broad-spectrum antibiotics to standard-spectrum alternatives. The research was based on pre-trial data from over 420,000 HCA Healthcare patients.

These INSPIRE trials address two of the four most common infections requiring hospitalization. HCA Healthcare is now implementing these protocols across its 190 hospitals, potentially improving care for millions of U.S. patients while helping combat the growing threat of antibiotic resistance.

HCA Healthcare (NYSE:HCA) has been recognized as a top performer on Fortune's 2025 World's Most Admired Companies list, ranking first in its industry. The recognition follows Fortune's analysis of 650 companies across 51 industries in 30 countries, evaluated on nine criteria including innovation, management quality, and financial soundness.

The healthcare provider, comprising approximately 316,000 colleagues, demonstrated significant community impact by deploying over 700 colleagues and contributing $1.5 million for hurricane relief during the 2024 Helene and Milton disasters. The company was also featured on Fortune's America's Most Innovative Companies list for its AI technologies and data-driven solutions implementation.

Notably, 33 HCA Healthcare hospitals were named on the 2025 Fortune/Premier 100 Top Hospitals list, spanning various categories including major teaching hospitals, teaching hospitals, and community hospitals of different sizes. The evaluation was based on clinical outcomes, operational efficiency, patient experience, and financial health metrics.

HCA Healthcare (NYSE: HCA) has scheduled its first quarter 2025 earnings conference call for Friday, April 25, 2025, at 9:00 AM Central Time (10:00 AM Eastern). The company will host a live audio webcast accessible through their investor relations website.

Investors and interested parties who cannot attend the live webcast can access the archived version of the call through HCA Healthcare's investor relations portal. For additional information, investors can contact Frank Morgan, Vice President of Investor Relations, while media inquiries should be directed to Harlow Sumerford.

HCA Healthcare (NYSE:HCA) has appointed Monica Cintado as senior vice president of development, succeeding Joseph A. Sowell who is retiring after more than 15 years of service. In her new role, Cintado will lead HCA Healthcare's enterprise development strategy, including mergers, acquisitions, divestitures, and strategic investments.

Cintado, who first joined HCA Healthcare in 1993, returned to the company in 2015 as vice president of development. She previously served as senior vice president of development at United Surgical Partners International. Her experience includes overseeing strategy, due diligence, negotiations, and regulatory approvals for acquisitions and divestitures.

HCA Healthcare Foundation has announced a $1.84 million grant to Mile High United Way through its Healthier Tomorrow Fund to launch United for Healthy Starts, a national collaboration between four United Ways. The initiative, involving United Ways in Denver, Dallas, Miami, and Nashville, aims to increase access to social, economic, and educational support services for families through home visitation and wrap-around services.

The program focuses on creating a national collaborative learning community to strengthen service delivery and achieve scalable impact. HCA Healthcare and its Foundation have a long-standing relationship with United Way, contributing over $17 million in support over the last 30 years. The Healthier Tomorrow Fund has committed more than $17 million in grants to various nonprofits across the country since its inception.

HCA Healthcare (NYSE:HCA) has achieved a significant milestone with 100 of its hospitals receiving the 2025 Patient Safety Excellence Award from Healthgrades, placing them in the top 10% of hospitals nationwide for patient safety. The recognition is based on risk-adjusted complication and mortality rates evaluated across approximately 4,500 hospitals.

Additionally, 49 HCA Healthcare hospitals were named among America's 250 Best Hospitals for 2025, representing the top 5% nationally for clinical excellence. The healthcare provider implements comprehensive safety measures through dedicated quality teams, including event reporting, serious event analysis, and advanced technologies like barcode medication administration.

HCA Healthcare's research contributions include notable studies such as the INSPIRE trials, CLUSTER trial, Swap Out trial, and ABATE Infection Trial, focusing on improving antibiotic stewardship, infection control, and patient safety. The organization's Patient Safety Organization (PSO) continues to enhance healthcare delivery through systematic improvements and fostering a culture of safety.

HCA Healthcare (NYSE:HCA) has been named one of the 2025 World's Most Ethical Companies by Ethisphere for the 15th time, standing as one of only three honorees in the Healthcare Providers category. The recognition follows a comprehensive assessment requiring over 240 proof points on ethics, compliance, governance, and social impact.

In 2024, HCA Healthcare demonstrated significant community impact through:

• $48 million in donations through HCA Healthcare and its Foundation
• $6.4 million in grants across 15 divisions via the Healthier Tomorrow Fund
• 240,000 volunteer hours from colleagues
• $4.4 billion in charity care and uncompensated care
• $1.5 million for hurricane relief efforts

The company's HCA Healthcare Hope Fund distributed $3.3 million in grants to over 3,500 colleagues in 2024, reaching a total of $115 million in lifetime distributions. Additionally, HCA Healthcare maintains strong support for employee well-being through programs like Nurse Care and the GME Physician Wellness Research Lab.